CAJ | 학술논문

目的探讨联合应用可溶性白介素5受体α (sIL-5Rα)及可溶性白介素13受体α2(sIL-13Rα2)对支气管哮喘(简称哮喘)动物血管细胞黏附分子1(VCAM-1)、信号转导和转录激活因子6( ST AT6)水平的影响.方法 50只BALB/c小鼠随机分为正常组、哮喘组、sIL-5Rα治疗组、sIL-13Rα2治疗组、联合sIL-5Rα及sIL-13Rα2治疗组(简称联合治疗组).哮喘组和治疗组用鸡卵蛋白(OVA)和氢氧化铝致敏,用OVA激发,建立小鼠哮喘模型,正常组用生理盐水代替,其中sIL-5Rα治疗组、sIL-13Rα2治疗组及联合治疗组分别于诱发前30 min给予腹腔注射100 μg sIL-5Rα、sIL-13Rα2及联合应用sIL-5Rα及sIL-13Rα2各100 μg,正常组和哮喘组激发前30 min给予腹腔注射相同体积生理盐水.ELISA双抗体夹心法测定各组血清VCAM-1水平变化,免疫组织化学法和反转录-聚合酶链反应(RT-PCR)法检测各组小鼠肺组织STAT6水平变化.结果与正常组比较,哮喘组VCAM-1、STAT6含量明显升高(P＜0.01)；联合治疗组可有效降低VCAM-1、STAT6含量,与哮喘组比较差异有统计学意义(P＜0.01)；与单独治疗组相比,联合治疗组效果更明显(P＜0.01).结论联合应用sIL-5Rα及sIL-13Rα2可显著降低VCAM-1、STAT6含量,从而达到缓解和治疗哮喘的目的.
목적 탐토연합응용가용성백개소5수체α (sIL-5Rα)급가용성백개소13수체α2(sIL-13Rα2)대지기관효천(간칭효천)동물혈관세포점부분자1(VCAM-1)、신호전도화전록격활인자6( ST AT6)수평적영향.방법 50지BALB/c소서수궤분위정상조、효천조、sIL-5Rα치료조、sIL-13Rα2치료조、연합sIL-5Rα급sIL-13Rα2치료조(간칭연합치료조).효천조화치료조용계란단백(OVA)화경양화려치민,용OVA격발,건립소서효천모형,정상조용생리염수대체,기중sIL-5Rα치료조、sIL-13Rα2치료조급연합치료조분별우유발전30 min급여복강주사100 μg sIL-5Rα、sIL-13Rα2급연합응용sIL-5Rα급sIL-13Rα2각100 μg,정상조화효천조격발전30 min급여복강주사상동체적생리염수.ELISA쌍항체협심법측정각조혈청VCAM-1수평변화,면역조직화학법화반전록-취합매련반응(RT-PCR)법검측각조소서폐조직STAT6수평변화.결과 여정상조비교,효천조VCAM-1、STAT6함량명현승고(P＜0.01)；연합치료조가유효강저VCAM-1、STAT6함량,여효천조비교차이유통계학의의(P＜0.01)；여단독치료조상비,연합치료조효과경명현(P＜0.01).결론 연합응용sIL-5Rα급sIL-13Rα2가현저강저VCAM-1、STAT6함량,종이체도완해화치료효천적목적.
Objective To investigate the effects of soluble interleukin-5 receptor α (sIL-5Rα) and soluble interleukin-13 receptorα2 (sIL-13Rα2) on VCAM-1 and STAT6 in bronchial asthma (asthma)animal.Methods A total of 50 BALB/c mice were randomly divided into 5 groups:the normal group,the asthmatic group,the sIL-5Rα treatment group,the sIL-13Rα2 treatment group,the combination of sIL5Rα and sIL-13Rα2 treatment group (the combined treatment group).Mice in the latter 4 groups were sensitized with ovalbumin (OVA) and Al (OH)3,and challenged with OVA to establish asthmatic models,while mice in the normal group were treated with saline.Mice in the sIL-5Rα treatment group,the sIL-13Rα2 treatment group and the combined treatment group were injected intraperitoneally with sIL-5Rα (100 μg),sIL-13Rα (100 μg) and the combination of sIL-5Rα (100 μg) and sIL-13Rα2 (100 μg)30 min before challenged,while mice in normal group and asthmatic group received saline. Then the VCAM-1 level of serum were measured by ELISA, and level of STAT6 were measured by immunohistochemically and RT-PCR.Results Compared with the normal group,the level of VCAM-1and STAT6 in the asthmatic group were higher (P ＜0.01 ).Compared with the asthmatic group,the combined treatment group can effectively reduced VCAM-1 and STAT6 level ( P ＜0.01).Compared with single treatment,combined treatment group were more effective ( P ＜0.01).Conclusions sIL-5Rα and sIL-13Rα2 inhibit IL-5 and IL-13 functions can reduce VCAM-1 and STAT6 levels,which achieve the purpose of mitigation and treatment of asthma.